Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics; Shares Delisted
SLNO sits 80% above its 52-week low of $29.43.
Summary
Neurocrine Biosciences has completed its acquisition of Soleno Therapeutics for $53.00 per share in cash, with Soleno now operating as a wholly-owned subsidiary and its shares delisted from Nasdaq.
Key Events · M&A and Partnerships · SLNO
-
Tender Offer Completed
Neurocrine Biosciences' tender offer for Soleno Therapeutics expired on May 15, 2026, with 46,356,114 shares, representing approximately 88.9% of outstanding shares, validly tendered.
-
Merger Consummated
All conditions to the offer were satisfied or waived, and the merger was completed on May 17, 2026, making Soleno a direct wholly-owned subsidiary of Neurocrine Biosciences.
-
Shares Delisted
Soleno's common stock will no longer be listed or traded on the Nasdaq Capital Market, effective May 18, 2026.
Analysis · SLNO · Life Sciences
This filing confirms the successful completion of Neurocrine Biosciences' tender offer and subsequent merger with Soleno Therapeutics. Soleno is now a wholly-owned subsidiary, and its common stock has been delisted from Nasdaq. This marks the definitive end of Soleno as an independent public company, providing a cash exit for shareholders and integrating its Prader-Willi syndrome drug, VYKAT XR, into Neurocrine's portfolio.
At the time of this filing, SLNO was trading at $52.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $29.43 to $90.32. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.